Hua Xiao

Hua Xiao

Auto-generated profile, based on publicly available information

Hua Xiao

State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic & Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LZLei Zhang
Lei Zhang
HXHua Xiao
Hua Xiao
SKScott Karlan
Scott Karlan
HZHui Zhou
Hui Zhou
JGJenny Gross
Jenny Gross
David WongDavid Wong
David Wong
A sensitive assay to identify biomarkers using non-invasively collected clinical specimens is ideal for breast cancer detection. While there are other studies showing disease biomarkers in saliva for breast cancer, our study tests the hypothesis that there are breast cancer discriminatory biomarkers in saliva using de novo discovery and validation approaches. This is the first study of this kind and no other study has engaged a de novo biomarker discovery approach in saliva for breast cancer detection. In this study, a case-control discovery and independent preclinical validations were conducted to evaluate the performance and translational utilities of salivary transcriptomic and proteomic biomarkers for breast cancer detection. Salivary transcriptomes and proteomes of 10 breast cancer patients and 10 matched controls were profiled using Affymetrix HG-U133-Plus-2.0 Array and two-dimensional difference gel electrophoresis (2D-DIGE), respectively. Preclinical validations were performed to evaluate the discovered biomarkers in an independent sample cohort of 30 breast cancer patients and 63 controls using RT-qPCR (transcriptomic biomarkers) and quantitative protein immunoblot (proteomic biomarkers). Transcriptomic and proteomic profiling revealed significant variations in salivary molecular biomarkers between breast cancer patients and matched controls. Eight mRNA biomarkers and one protein biomarker, which were not affected by the confounding factors, were pre-validated, yielding an accuracy of 92% (83% sensitive, 97% specific) on the preclinical validation sample set. Our findings support that transcriptomic and proteomic signatures in saliva can serve as biomarkers for the non-invasive detection of breast cancer. The salivary biomarkers possess discriminatory power for the detection of breast cancer, with high specificity and sensitivity, which paves the way for prediction model validation study followed by pivotal clinical validation.

28 March 2012 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
DEDavid Elashoff
David Elashoff
HZHui Zhou
Hui Zhou
JRJean Reiss
Jean Reiss
JWJianghua Wang
Jianghua Wang
HXHua Xiao
Hua Xiao
DWDavid T.W. Wong
David T.W. Wong
Background: Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL). Methods: Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL. Results: Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts. Conclusions: The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies. Impact: Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects. Cancer Epidemiol Biomarkers Prev; 21(4); 664–72. ©2012 AACR.

1 February 2012 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
HXHua Xiao
Hua Xiao
LZLei Zhang
Lei Zhang
HZHui Zhou
Hui Zhou
JLJay M. Lee
Jay M. Lee
EGEdward B. Garon
Edward B. Garon
DWDavid T. W. Wong
David T. W. Wong
Lung cancer is often asymptomatic or causes only nonspecific symptoms in its early stages. Early detection represents one of the most promising approaches to reduce the growing lung cancer burden. Human saliva is an attractive diagnostic fluid because its collection is less invasive than that of tissue or blood. Profiling of proteins in saliva over the course of disease progression could reveal potential biomarkers indicative of oral or systematic diseases, which may be used extensively in future medical diagnostics. There were 72 subjects enrolled in this study for saliva sample collection according to the approved protocol. Two-dimensional difference gel electrophoresis combined with MS was the platform for salivary proteome separation, quantification, and identification from two pooled samples. Candidate proteomic biomarkers were verified and prevalidated by using immunoassay methods. There were 16 candidate protein biomarkers discovered by two-dimensional difference gel electrophoresis and MS. Three proteins were further verified in the discovery sample set, prevalidation sample set, and lung cancer cell lines. The discriminatory power of these candidate biomarkers in lung cancer patients and healthy control subjects can reach 88.5% sensitivity and 92.3% specificity with AUC = 0.90. This preliminary data report demonstrates that proteomic biomarkers are present in human saliva when people develop lung cancer. The discriminatory power of these candidate biomarkers indicate that a simple saliva test might be established for lung cancer clinical screening and detection.

13 February 2018 in Journal of Proteome Research
Verified
Journal Article
Closed access
YSYan Sun
Yan Sun
CHChunhui Huo
Chunhui Huo
ZQZhi Qiao
Zhi Qiao
ZSZhi Shang
Zhi Shang
AUAsad Uzzaman
Asad Uzzaman
HXHua Xiao
Hua Xiao

12 June 2012 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
LZLei Zhang
Lei Zhang
HXHua Xiao
Hua Xiao
HZHui Zhou
Hui Zhou
SSSilverio Santiago
Silverio Santiago
JLJay M. Lee
Jay M. Lee
David WongDavid Wong
David Wong

1 August 2017 in Analytica Chimica Acta
Verified
Journal Article
Closed access
YSYan Sun
Yan Sun
SLSha Liu
Sha Liu
ZQZhi Qiao
Zhi Qiao
ZSZhi Shang
Zhi Shang
ZXZhijun Xia
Zhijun Xia
HXHua Xiao
Hua Xiao